pyrroles has been researched along with Cancer of Gastrointestinal Tract in 109 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (8.26) | 29.6817 |
| 2010's | 89 (81.65) | 24.3611 |
| 2020's | 11 (10.09) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, K; Shu, M; Wang, X; Zhang, H | 1 |
| DuBois, SG; Khosravan, R; Wetmore, C; Yu, Y | 1 |
| Gennatas, S; Huang, P; Jones, RL; Smrke, A | 1 |
| Bauer, S; Cassier, PA; Chawla, SP; Eskens, F; Evans, EK; George, S; Heinrich, MC; Jones, RL; Kang, YK; Lauz, T; Mir, O; Roche, M; Rutkowski, P; Schöffski, P; Serrano, C; Tap, WD; Trent, J; Tugnait, M; von Mehren, M; Wolf, BB; Zhou, T | 1 |
| Wang, M; Zhao, G; Zhao, WY | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Bauer, S; Cassier, PA; Chawla, SP; Eskens, FALM; George, S; Heinrich, MC; Jones, RL; Kang, YK; Mir, O; Roche, M; Rutkowski, P; Schöffski, P; Serrano, C; Tap, WD; von Mehren, M; Zhou, T | 1 |
| DuBois, SG; Khosravan, R; Verschuur, AC; Wang, E; Wetmore, C | 1 |
| Serrano, C | 1 |
| Bauer, S; Brahmi, M; George, S; He, K; Heinrich, MC; Hew, P; Hohenberger, P; Jones, RL; Kang, YK; Mir, O; Newberry, K; Pantaleo, MA; Patel, S; Roche, M; Rutkowski, P; Schöffski, P; Shen, L; Tap, WD; Trent, J; Villalobos, V; von Mehren, M; Zhou, Y | 1 |
| Cubedo, R; García Del Muro, X; López-Guerrero, JA; Martín-Broto, J; Martínez, V; Poveda, A; Romero, I; Serrano, C; Valverde, C | 1 |
| Yousef, AJA | 1 |
| Benson, C; Chou, AJ; Magnan, H; Rutkowski, P | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Saito, Y; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Allenspach, K; Berger, EP; Du, Y; Fox, LE; Jergens, AE; Johannes, CM; Mochel, JP; Musser, ML; Powers, BE | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khromova, N; Kopnin, P; Micheeva, E; Novikova, M | 1 |
| Adamson, T; Antonescu, CR; Chi, P; Condy, M; D'Angelo, SP; Dickson, MA; Gounder, M; Hwang, S; Kelly, C; Keohan, ML; Mcfadyen, CR; Movva, S; Qin, LX; Rosenbaum, E; Singer, S; Tap, WD | 1 |
| Gao, J; Li, J; Shen, L; Sun, N; Tian, Y; Yuan, J | 1 |
| Libutti, SK; Saif, MW; Stevenson, R | 1 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Nishida, T; Tori, M; Yoshidome, K | 1 |
| Chen, ZF; Chi, P; Guan, GX; Jiang, WZ; Liu, X; Lu, HS | 1 |
| Cao, H; Xu, J | 1 |
| Bracci, R; Cascinu, S; Maccaroni, E | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| De Giorgi, U | 1 |
| Akça, Z; Büyükçelik, A; Kaya, N; Mutlu, H | 1 |
| Lyseng-Williamson, KA | 1 |
| Liu, S; Yu, L | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Liang, H | 1 |
| Liang, X; Shi, Y | 1 |
| Doi, T; Naito, Y; Nishida, T | 1 |
| Allred, R; de Wit, D; Demetri, GD; Gelderblom, H; Guchelaar, HJ; Khosravan, R; van Erp, NP; Wiltshire, R | 1 |
| Chen, JS; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Hsu, CC; Jan, YY; Liu, YY; Tsai, CY; Tseng, JH; Wu, CE; Yeh, CN; Yeh, TS | 1 |
| Liu, K; Wen, Y; Wu, L; Xiong, L; Yao, H; Zhang, Z | 1 |
| Boglione, A; Comandone, A | 1 |
| Biasco, G; Chen, L; Demetri, GD; Fly, K; Fumagalli, E; Gelderblom, H; Hurwitz, HI; Kaiser, PE; Kang, YK; Lechuga, MJ; Matczak, E; Reichardt, P; Rosen, LS; Rutkowski, P; Schuette, J; Seddon, B; Williams, CC; Yalcin, S | 1 |
| Demetri, GD; Doi, T; Kanda, T; Komatsu, Y; Kuss, I; Nishida, T; Sawaki, A; Yamada, Y | 1 |
| Bencsikova, B; Bortlicek, Z; Brabec, P; Jureckova, A; Kocak, I; Kocakova, I; Krejci, E; Spelda, S; Strenkova, J; Vyzula, R | 1 |
| Antonescu, CR; Beckman, MJ; Besmer, P; Cohen, NA; Crawley, MH; DeMatteo, RP; Green, BL; Greer, JB; Kim, TS; Rossi, F; Santamaria-Barria, JA; Seifert, AM; Sorenson, EC; Zeng, S | 1 |
| Pilotte, AP | 1 |
| He, Y; Zhang, X | 1 |
| Boccardi, V; Marano, L; Marrelli, D; Roviello, F | 1 |
| Cottle-Delisle, C; Kebebew, E; Marx, S; Meltzer, P; Merkel, R; Neychev, V; Nilubol, N; Pacak, K; Steinberg, SM; Yao, J | 1 |
| Kato, S | 1 |
| Houzawa, H; Komatsu, Y; Nishida, T; Ohki, E; Togo, K; Toyoshima, Y; Ueda, E; Ueno, N; Yoshida, A | 1 |
| Berardi, R; Caramanti, M; Cascinu, S; Falconi, M; Morgese, F; Onofri, A; Pagliaretta, S; Partelli, S; Polenta, V; Rinaldi, S; Torniai, M | 1 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakada, N; Nanjyo, S; Sugiyama, T | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khaibullina, S; Khusnutdinov, R; Lombardi, V; Ramazanov, B; Zykova, S | 1 |
| Boddy, AV; Galettis, P; Goulooze, SC; Martin, JH | 1 |
| Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E | 1 |
| Maki, RG; Martínez-Marín, V | 1 |
| Angenendt, P; Diehl, F; Fredebohm, J; Holtrup, F; Löber, AK; Mehnert, DH; van Rahden, V | 1 |
| Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH | 1 |
| Chen, TW; Chen, YY; Chiang, KC; Liu, CT; Liu, YY; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS | 1 |
| Adachi, Y; Arimura, Y; Carbone, DP; Ii, M; Imai, K; Imsumran, A; Lee, CT; Li, H; Li, R; Maehata, T; Piao, W; Shinomura, Y; Wang, Y; Yamamoto, H | 1 |
| Adachi, Y; Arimura, Y; Carbone, DP; Imai, K; Imsumran, A; Lee, CT; Li, H; Li, R; Min, Y; Piao, W; Shinomura, Y; Wang, Y; Yamamoto, H | 1 |
| Dreyer, C; Faivre, S; Raymond, E; Theou-Anton, N | 1 |
| Reichardt, P | 1 |
| Antón-Aparicio, LM; Calvo, OF; Carral, A; Durana, J; García-Campelo, R; Grande, E; López, MR; Quindós, M; Soto, JM; Vázquez, DD | 1 |
| Gasent, JM; Grande, E; Grávalos, C | 1 |
| Dimou, AT; Saif, MW; Syrigos, KN | 1 |
| Liang, ZY | 1 |
| Dudeck, O; Pink, D; Reichardt, P; Zeile, M | 1 |
| Raut, CP; Winer, JH | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Hanazaki, K; Ikezoe, T; Nishioka, C; Taguchi, T; Takezaki, Y; Yang, J; Yokoyama, A | 1 |
| Blanke, CD; Picus, J; Pisters, PWT; Sirulnik, A; Stealey, E; Trent, JC; von Mehren, M | 1 |
| Debiec-Rychter, M; Faa, G; Floris, G; Normant, E; Schöffski, P; Sciot, R; Van Looy, T; Wellens, J; Wozniak, A | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, SH; Kim, TM; Kim, TY; Kim, WH; Koh, Y; Lee, HE; Lee, SH; Oh, DY | 1 |
| Cunningham, D; Yim, KL | 1 |
| Reichardt, A; Reichardt, P | 1 |
| Yim, KL | 1 |
| Deol, R; Lamba, G; Malhotra, BK; Sahni, R; Shah, D | 1 |
| Kwak, JY; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Nagahama, K; Takahashi, D; Tamura, T; Tanaka, H; Tsuura, Y | 1 |
| Patil, DT; Rubin, BP | 1 |
| Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R | 1 |
| Patel, S | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Caram, MV; Schuetze, SM | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Blay, JY; Bui-Nguyen, B; Demetri, GD; Galetic, I; Gelderblom, H; Hsu, Y; McArthur, GA; Reichardt, P; Rutkowski, P; Schlemmer, M; Yazji, S | 1 |
| Brzeskwiniewicz, M; Bylina, E; Falkowski, S; Grzesiakowska, U; Klimczak, A; Kroc, J; Limon, J; Lugowska, I; Melerowicz, W; Mierzejewska, E; Nowecki, ZI; Osuch, C; Rutkowski, P; Siedlecki, JA; Switaj, T; Wasielewski, K; Woźniak, A | 1 |
| Heymach, JV; Mateo, J; Zurita, AJ | 1 |
| Koshenkov, VP; Rodgers, SE | 1 |
| Benavent, M; de Miguel, MJ; Garcia-Carbonero, R | 1 |
| Lai, EC; Lau, SH; Lau, WY | 1 |
| Gao, J; Hong, J; Li, J; Shen, L | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Xu, JM | 1 |
| Donohue, JH; Nagorney, DM; Okuno, SH; Que, FG; Zaydfudim, V | 1 |
| Cohen, DP; Demetri, GD; George, S; Lechner, T; Li, S; Reichardt, P | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Hiramatsu, Y; Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T | 1 |
| Nishida, T; Ueshima, S; Wakasugi, M | 1 |
| Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Akyol, M; Alacacioglu, A; Benekli, M; Buyuberber, S; Ciltas, A; Coskun, U; Dane, F; Gumus, M; Isikdogan, A; Kaplan, MA; Karaca, H; Kefeli, U; Ozdemir, N; Ozkan, M; Seker, M; Sevinc, A; Suner, A; Tarhan, MO; Yildiz, R | 1 |
| Cunningham, D; Waddell, T | 1 |
| Badalamenti, G; Bauer, S; Blackstein, M; Blay, JY; Casali, PG; Chung, J; Demetri, GD; Gelderblom, H; Hohenberger, P; Joensuu, H; Kang, YK; Kappeler, C; Kuss, I; Laurent, D; Le Cesne, A; Leahy, M; Maki, RG; Nguyen, BB; Nishida, T; Reichardt, P; Rutkowski, P; Schöffski, P; von Mehren, M; Xu, J | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schöfl, C | 1 |
| Fletcher, CD; Hornick, JL | 1 |
| Reid, TR; Saylor, PJ | 1 |
| Shen, L | 1 |
| Hopkins, TG; Marples, M; Stark, D | 1 |
35 review(s) available for pyrroles and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Topics: Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Standard of Care; Triazines | 2020 |
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Infant; Male; Models, Biological; Neoplasms; Pyrroles; Sunitinib; Young Adult | 2021 |
New treatments in advanced gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines; Urea | 2021 |
GEIS guidelines for gastrointestinal sarcomas (GIST).
Topics: Antineoplastic Agents; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Sunitinib | 2017 |
Novel agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib | 2013 |
[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2013 |
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Topics: Animals; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Mimicry; Protein Interaction Domains and Motifs; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2013 |
Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome | 2014 |
Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Gastrointestinal; Endosonography; Europe; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Mutation; Pancreaticoduodenectomy; Phenylurea Compounds; Piperazines; Prevalence; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sex Distribution; Sunitinib; United States | 2015 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Topics: Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Liver Neoplasms; Neuroendocrine Tumors; Pyrroles; Somatostatin; Sunitinib | 2016 |
Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoadjuvant Therapy; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2016 |
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Pyrroles; Risk Assessment; Sunitinib | 2009 |
[Internal medical therapy of gastrointestinal stroma tumors].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2009 |
Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Congresses as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sirolimus; Sunitinib | 2010 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Topics: Alleles; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; DNA Mutational Analysis; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Maintenance Chemotherapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Endocrine Gland Neoplasms; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Gastrointestinal stromal tumor: advances in diagnosis and management.
Topics: Benzamides; Diagnosis, Differential; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Interleukin-8; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Adjuvant therapy of gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2012 |
Current management of gastrointestinal stromal tumors--a comprehensive review.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2007 |
Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib; Treatment Outcome | 2008 |
16 trial(s) available for pyrroles and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Topics: Aged; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; Prognosis; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines | 2020 |
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Triazines | 2021 |
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Disease Progression; Drug Administration Schedule; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; North America; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Triazines | 2021 |
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Tissue Distribution | 2019 |
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Child; Diarrhea; Disease-Free Survival; Fatigue; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Double-Blind Method; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib; Survival Analysis; Young Adult | 2015 |
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tria
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cytoreduction Surgical Procedures; Digestive System Neoplasms; Disease-Free Survival; Everolimus; Gastrointestinal Neoplasms; Gastrointestinal Tract; Genotype; Humans; Indoles; Mutation; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Prospective Studies; Pyrroles; Research Design; Sunitinib | 2015 |
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hand-Foot Syndrome; Humans; Incidence; Indoles; Japan; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Pyrroles; Severity of Illness Index; Sunitinib; Thrombocytopenia; Treatment Outcome | 2015 |
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.
Topics: Adult; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Models, Statistical; Nonlinear Dynamics; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Survival Analysis; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, Community; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Registries; Sunitinib; United States; Young Adult | 2011 |
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Child; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Indoles; Kidney Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Double-Blind Method; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Survival Rate; Treatment Failure | 2013 |
59 other study(ies) available for pyrroles and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
Topics: Administration, Oral; Adolescent; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Dosage Calculations; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Young Adult | 2020 |
[Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Molecular Targeted Therapy; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Triazines | 2020 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |
Jejunal Gastrointestinal Stromal Tumor.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Jejunal Neoplasms; Jejunum; Male; Pyrroles; Sunitinib | 2017 |
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Topics: Adolescent; Antineoplastic Agents; Child; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome; United States; Young Adult | 2017 |
[Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Topics: Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Sunitinib | 2018 |
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Indoles; Male; Mitotic Index; Prognosis; Progression-Free Survival; Pyrroles; Retrospective Studies | 2018 |
Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Mice; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
[Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2012 |
[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2013 |
Transient sunitinib resistance in gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Exanthema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2014 |
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Young Adult | 2014 |
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Treatment Outcome; Young Adult | 2014 |
[The importance of mutational status in prognosis and therapy of GIST].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib | 2015 |
Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Time Factors | 2015 |
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles; Sunitinib | 2015 |
[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrroles; Rectal Neoplasms; Sunitinib | 2016 |
Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboxylic Acids; Cell Death; Cell Growth Processes; Cell Line, Tumor; G2 Phase Cell Cycle Checkpoints; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Leiomyosarcoma; M Phase Cell Cycle Checkpoints; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Tubulin; Tubulin Modulators | 2016 |
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Computer Simulation; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Monte Carlo Method; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2016 |
Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Outcome Assessment, Health Care; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Pyrroles; Reproducibility of Results; Sunitinib | 2016 |
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult | 2017 |
Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Postoperative Complications; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Gastrointestinal Neoplasms; Humans; Insulin; Mice; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Topics: Adenocarcinoma; Animals; Blotting, Western; Female; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Genes, Dominant; Humans; Immunoenzyme Techniques; Immunoprecipitation; Infusions, Subcutaneous; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Somatomedins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
Topics: Adrenalectomy; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Treatment Outcome | 2010 |
The potential role of sunitinib in gastrointestinal cancers other than GIST.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Pyrroles; Sunitinib | 2010 |
[The role of pathologists in the target therapy of gastrointestinal tumors].
Topics: Anoctamin-1; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chloride Channels; Drug Delivery Systems; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Membrane Proteins; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Tomography, Emission-Computed | 2011 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Sunitinib | 2012 |
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Sunitinib and Thrombosis.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Thrombosis | 2012 |
Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Brain Diseases, Metabolic; Confusion; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2011 |
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
Topics: Aged; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney; Male; Nephrotic Syndrome; Proteinuria; Pyrroles; Sunitinib | 2012 |
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome | 2011 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Multivariate Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2012 |
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Asian People; Benzamides; China; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2012 |
[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Gastrointestinal Neoplasms; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Peptides, Cyclic; Pyrroles; Sirolimus; Somatostatin; Sunitinib | 2012 |
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Minnesota; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib | 2012 |
Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Recurrence; Sunitinib | 2012 |
[Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Turkey | 2013 |
Evaluation of regorafenib in colorectal cancer and GIST.
Topics: Antineoplastic Agents; Benzamides; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2013 |
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2012 |
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Topics: Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Cycle; Doxorubicin; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Gastrointestinal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroendocrine Tumors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2006 |
Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Topics: Administration, Oral; Antineoplastic Agents; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Lysis Syndrome | 2007 |
[Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; ErbB Receptors; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |